ArticleFrontiers in medicine2026
Impacts of hemoperfusion combined with continuous renal replacement therapy on renal function and immune function in patients with acute renal failure caused by poisoning.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the clinical efficacy of hemoperfusion (HP) plus continuous renal replacement therapy (CRRT) in patients with poisoning-induced acute renal failure (ARF), with particular focus on renal function recovery and immune function modulation. Methods: One hundred and sixteen patients with poisoning-induced ARF admitted to our hospital from March 2022 to March 2025 were enrolled and randomly divided into the single group receiving CRRT alone and the study group receiving HP + CRRT. The primary outcome was the reduction in serum creatinine (Scr) at 72 h post-treatment. Secondary outcomes included blood urea nitrogen (BUN), 24-h urine output, time to CRRT independence, proportion of patients achieving complete renal recovery at 28 days, immune function parameters, inflammatory markers, disease severity scores, clinical outcomes, and adverse events. Results: The combination group presented better renal function recovery, with lower serum creatinine and blood urea nitrogen levels at 48 h, 72 h, and 7 days post-treatment, and higher 24-h urine output at all time points ( Conclusion: HP combined with CRRT significantly improves renal function recovery and enhances immune function in patients with poisoning-induced ARF compared to CRRT alone, potentially by removing circulating toxins and inflammatory mediators while modulating the systemic inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.